6733 Stock Overview
Develops regenerative bio-orthopaedic products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioGend Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$33.20 |
| 52 Week High | NT$42.30 |
| 52 Week Low | NT$31.40 |
| Beta | 0.65 |
| 1 Month Change | -7.52% |
| 3 Month Change | -12.63% |
| 1 Year Change | -13.20% |
| 3 Year Change | 26.24% |
| 5 Year Change | 14.09% |
| Change since IPO | 0.30% |
Recent News & Updates
Shareholder Returns
| 6733 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -3.2% | -0.6% | -1.8% |
| 1Y | -13.2% | 4.3% | 27.9% |
Return vs Industry: 6733 underperformed the TW Biotechs industry which returned 4.6% over the past year.
Return vs Market: 6733 underperformed the TW Market which returned 28.8% over the past year.
Price Volatility
| 6733 volatility | |
|---|---|
| 6733 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6733 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6733's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.biogend.com |
BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd. Fundamentals Summary
| 6733 fundamental statistics | |
|---|---|
| Market cap | NT$4.13b |
| Earnings (TTM) | -NT$109.93m |
| Revenue (TTM) | NT$156.64m |
26.3x
P/S Ratio-37.5x
P/E RatioIs 6733 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6733 income statement (TTM) | |
|---|---|
| Revenue | NT$156.64m |
| Cost of Revenue | NT$30.49m |
| Gross Profit | NT$126.16m |
| Other Expenses | NT$236.09m |
| Earnings | -NT$109.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 80.54% |
| Net Profit Margin | -70.18% |
| Debt/Equity Ratio | 0% |
How did 6733 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 05:10 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioGend Therapeutics Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Corp. |